Sue Griffin, CSO at the Centre for Drug Development, shared a post on LinkedIn by Lars Erwig, Director Centre of Drug Development Cancer Research UK, adding:
“After 12 fantastic years at GSK, I’m pleased to share the news that I’m starting a new role as CSO at the Centre for Drug Development. I’m thrilled to be joining a fantastic team and to have such an amazing opportunity to help bring drugs to oncology patients with unmet need.
I also want to reflect and thank all of the brilliant people that I’ve worked with at GSK over the years and especially to those who have helped me to grow and have such a great career at GSK. There’s too many of you to name, but you know who you are – thank you. I’ll be watching and wishing for GSK’s success from afar.”
Quoting Lars Erwig‘s post:
“I’m pleased to announce the appointment of Sue Griffin as Chief Scientific Officer for the Centre for Drug Development.
Sue brings an outstanding breadth of experience across oncology drug discovery and development, with a proven track record of advancing innovative therapies from discovery through to clinical investigation.
She joins us from GSK, where she was Vice President of Translational Haematology and Tumour Omics and a member of the Oncology Translational Research Leadership Team, leading translational strategies and multidisciplinary teams, integrating multi-omics platforms and AI/machine learning to enable patient stratification, mechanism-of-action exploration and rational combination strategies.
With a PhD in T-cell haematology and experience spanning both the pharmaceutical and biotech sectors, her expertise will be instrumental as we continue to deliver early-phase clinical trials and bring more treatment options to cancer patients.”
